|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | ||
| Non-cash operating lease expense | ||
| Gain on lease modification | ||
| Equity-based compensation | ||
| Change in fair value of warrant liability | ||
| Amortization and accretion of marketable securities | ||
| Gain on Hit Discovery divestiture | ||
| Interest income on cash payments from Valo Health | ||
| Loss on sale and disposal of property and equipment | ||
| Changes in operating assets and liabilities: | ||
| Decrease in accounts receivable | ||
| Decrease (increase) in income taxes receivable | ||
| (increase) in prepaid expenses and other current assets | ||
| Increase (decrease) in accounts payable | ||
| Increase (decrease) in accrued expenses and other current liabilities | ||
| Increase (decrease) in income taxes payable | ||
| (Decrease) in deferred rent, noncurrent | ||
| (Decrease) in operating lease liability | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities | ||
| Purchases of held-to-maturity marketable securities | ||
| Proceeds from maturity and redemption of marketable securities | ||
| Proceeds from sale of property and equipment | ||
| Purchases of property and equipment | ||
| Net proceeds from Hit Discovery divestiture | ||
| Hit Discovery Divestiture | ||
| Total net proceeds from Hit Discovery divestiture | ||
| Net cash used in investing activities | ||
| Cash flows from financing activities | ||
| Proceeds from initial public offering of common stock, net of issuance costs | ||
| Proceeds from follow-on public offering of common stock, net of issuance costs | ||
| Proceeds from exercise of warrants to purchase common stock | ||
| Proceeds from exercise of options to purchase common stock | ||
| Payment of issuance costs on Series D redeemable convertible preferred stock | ||
| Payment of public offering costs | ||
| Net cash (used in) provided by financing activities | ||
| Net increase in cash, cash equivalents and restricted cash | ||
| Cash, cash equivalents and restricted cash, beginning of the year | ||
| Cash, cash equivalents and restricted cash, end of the year | ||
| Supplemental cash flow information: | ||
| Cash paid for income taxes | ||
| Supplemental disclosure of non-cash activities: | ||
| Operating lease right-of-use asset recognized upon adoption of Topic 842 | ||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | ||
| Accretion of cumulative dividends and issuance costs on preferred securities | ||
| Public offering costs included in accounts payable and accrued expenses | ||
| Net exercise of warrants to purchase common stock | ||
| Equity Consideration received in the Hit Discovery divestiture (Note 17) | ||
| Hit Discovery Divestiture | ||
| Total equity Consideration received in the Hit Discovery divestiture (Note 17) | ||
| Conversion of enterprise junior stock into common stock | ||
| Conversion of redeemable convertible and convertible preferred stock into common stock |
Loading...
